Celsus Therapeutics Announces That the Phase II Trial of MRX-6 Cream 2% in Pediatric Atopic Dermatitis Did Not Reach Primary Endpoint
February 17, 2015 07:00 ET
|
Celsus Therapeutics
NEW YORK and LONDON, Feb. 17, 2015 (GLOBE NEWSWIRE) -- Celsus Therapeutics (Nasdaq:CLTX), an emerging growth, development-stage biopharmaceutical company, announced today the results from C012013, a...
Celsus Therapeutics Completes Enrollment of Phase II Trial of MRX-6 Cream 2% in Pediatric Atopic Dermatitis
January 13, 2015 07:00 ET
|
Celsus Therapeutics
NEW YORK and LONDON, Jan. 13, 2015 (GLOBE NEWSWIRE) -- Celsus Therapeutics (Nasdaq:CLTX), an emerging growth, development-stage biopharmaceutical company, announced today that the Company has...
Celsus Therapeutics Announces FDA Allowance of IND for Clinical Development of MRX-6 Cream in Atopic Dermatitis
January 12, 2015 07:00 ET
|
Celsus Therapeutics
NEW YORK and LONDON, Jan. 12, 2015 (GLOBE NEWSWIRE) -- Celsus Therapeutics (Nasdaq:CLTX), an emerging growth, development-stage biopharmaceutical company, announced today that the U.S. Food and Drug...
Celsus Therapeutics Announces Upcoming Presentation at Oppenheimer 25th Annual Healthcare Conference
December 02, 2014 07:30 ET
|
Celsus Therapeutics
NEW YORK and LONDON, Dec. 2, 2014 (GLOBE NEWSWIRE) -- Celsus Therapeutics (Nasdaq:CLTX), an emerging growth, development-stage biopharmaceutical company, announces that Gur Roshwalb, MD, chief...
Celsus Therapeutics Plc Announces First Patient Enrolled in Phase II Trial of MRX-6 in Pediatric Atopic Dermatitis
August 06, 2014 07:30 ET
|
Celsus Therapeutics
NEW YORK and LONDON, Aug. 6, 2014 (GLOBE NEWSWIRE) -- Celsus Therapeutics Plc (Nasdaq:CLTX), an emerging growth, development-stage biotech company, announced the first patient has been enrolled in its...
Celsus Therapeutics Plc Receives Approval From the Ministry of Health of Israel for Phase II Trial of MRX-6 in Pediatric Atopic Dermatitis Patients
June 17, 2014 07:10 ET
|
Celsus Therapeutics
NEW YORK and LONDON, June 17, 2014 (GLOBE NEWSWIRE) -- Celsus Therapeutics Plc (Nasdaq:CLTX), an emerging growth, development-stage biotech company, has received approval from the Israeli Ministry of...
Celsus Therapeutics PLC Announces Details of Annual General Meeting of Shareholders
May 14, 2014 16:05 ET
|
Celsus Therapeutics
NEW YORK and LONDON, May 14, 2014 (GLOBE NEWSWIRE) -- Celsus Therapeutics Plc (Nasdaq:CLTX), an emerging growth, development-stage biotech company, announced today that the annual general meeting of...
Celsus Therapeutics Plc Announces Formation of New Dermatology Scientific Advisory Board
April 07, 2014 07:30 ET
|
Celsus Therapeutics
NEW YORK and LONDON, April 7, 2014 (GLOBE NEWSWIRE) -- Celsus Therapeutics Plc (Nasdaq:CLTX), an emerging growth, development-stage biotech company, announced today the formation of a new Dermatology...
Celsus Therapeutics Plc to Present at the 13th Annual Needham Healthcare Conference
March 31, 2014 16:05 ET
|
Celsus Therapeutics
NEW YORK and LONDON, March 31, 2014 (GLOBE NEWSWIRE) -- Celsus Therapeutics Plc (Nasdaq:CLTX), an emerging growth, development-stage biotech company, announced today that Dr. Gur Roshwalb, Chief...
Celsus Therapeutics Provides Year End 2013 Financial Results and Corporate Highlights
March 24, 2014 16:05 ET
|
Celsus Therapeutics
NEW YORK and LONDON, March 24, 2014 (GLOBE NEWSWIRE) -- Celsus Therapeutics Plc (Nasdaq:CLTX), an emerging growth, development-stage biotech company, today announced its financial results and provided...